See more : Kazera Global plc (KZG.L) Income Statement Analysis – Financial Results
Complete financial analysis of SeaStar Medical Holding Corporation (ICU) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SeaStar Medical Holding Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Extreme Networks, Inc. (EXTR) Income Statement Analysis – Financial Results
- Chinese Maritime Transport Ltd. (2612.TW) Income Statement Analysis – Financial Results
- Net One Systems Co., Ltd. (7518.T) Income Statement Analysis – Financial Results
- G3 VRM Acquisition Corp. (GGGVR) Income Statement Analysis – Financial Results
- La Rosa Holding Corp. Common Stock (LRHC) Income Statement Analysis – Financial Results
SeaStar Medical Holding Corporation (ICU)
About SeaStar Medical Holding Corporation
SeaStar Medical Holding Corporation, a medical device company, focuses on providing novel solutions and services to treat hyperinflammation and cytokine storm in critically ill patients. The company is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. It is developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure with and without LVAD; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is based in Denver, Colorado.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5.97M | 2.82M | 2.77M | 4.03M |
| General & Administrative | 8.01M | 6.60M | 1.68M | 2.43M |
| Selling & Marketing | 32.00K | 0.00 | 0.00 | 0.00 |
| SG&A | 8.04M | 6.60M | 1.68M | 2.43M |
| Other Expenses | 200.00K | 0.00 | 91.00K | 84.00K |
| Operating Expenses | 14.21M | 11.61M | 4.45M | 6.45M |
| Cost & Expenses | 14.21M | 11.61M | 4.45M | 6.45M |
| Interest Income | 0.00 | 630.00 | 212.00 | 3.31K |
| Interest Expense | 1.08M | 630.00K | 212.00K | 3.31M |
| Depreciation & Amortization | 14.01M | 11.61M | 4.45M | 6.45M |
| EBITDA | -11.14M | -11.61M | 0.00 | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -14.21M | -11.61M | -4.45M | -6.45M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -12.02M | -11.40M | -148.00K | 3.19M |
| Income Before Tax | -26.23M | -23.01M | -4.60M | -3.27M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.00K | -1.00K | 9.00K |
| Net Income | -26.23M | -23.01M | -4.60M | -3.28M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -30.29 | -70.16 | -15.90 | -27.15 |
| EPS Diluted | -30.26 | -70.07 | -15.87 | -27.15 |
| Weighted Avg Shares Out | 866.00K | 328.00K | 289.00K | 120.67K |
| Weighted Avg Shares Out (Dil) | 866.81K | 328.45K | 289.55K | 120.67K |
SeaStar Medical to Hold Business Update Conference Call on December 11, 2024
DENVER, Dec. 04, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that management will hold a conference call to discuss...
SeaStar Medical to Present at Noble Capital Markets' NobleCon20 on December 4, 2024
DENVER, Nov. 26, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that management will present a company overview at NobleCon20,...
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Support SeaStar Medical's Proposals to Ratify the Issuance of Shares and to Reduce the Number of Authorized Shares
SeaStar Medical urges stockholders to vote FOR all proxy proposals prior to the Special Meeting of Stockholders to be held November 26, 2024
SeaStar Medical Reaches Milestone of 100th QUELIMMUNE Commercial Device as Shipments Begin to its Third Hospital Customer
DENVER, Nov. 15, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, has begun shipping QUELIMMUNE™ to a third hospital customer. QUELIMMUNE...
SeaStar Medical Reports Third Quarter 2024 Financial Results and Provides a Business Update
DENVER, Nov. 13, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the...
ICU Medical, Inc. and Otsuka Pharmaceutical Factory, Inc., a Subsidiary of Otsuka Holdings Co. Ltd., Announce Creation of a Joint Venture to Bolster IV Solutions Manufacturing and Innovation in North America
The partnership creates one of the largest global IV solutions manufacturing networks with combined production of an estimated 1.4 billion annual units and aims to bring additional supply chain resiliency and new innovation to the North American IV solutions market....
ICU Medical to Participate at the UBS Global Healthcare Conference
SAN CLEMENTE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- ICU Medical (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the UBS Global Healthcare Conference being held in...
Record Monthly Enrollment Achieved in SeaStar Medical's Pivotal Adult AKI Trial
DENVER, Nov. 01, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports setting a new monthly enrollment record with 10 critically...
SeaStar Medical Adds Second Hospital Customer for QUELIMMUNE
DENVER, Oct. 31, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, has shipped QUELIMMUNE™ directly to a second hospital customer. QUELIMMUNE...
ICU Medical Announces Time of Third Quarter 2024 Earnings Conference Call
SAN CLEMENTE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its third quarter 2024 earnings release and conference call.
Source: https://incomestatements.info
Category: Stock Reports